Results 181 to 190 of about 56,276 (247)
Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis. [PDF]
Zhang H+5 more
europepmc +1 more source
Lanthanide‐based luminescence nanothermometry holds multifaceted potential for nanomedical applications, yet despite significant research advances, clinical translation of the engineered nanomaterials is still controversial and widely disputed. This is related to crucial nanotoxicological aspects that must be addressed at the preclinical level ...
Simona Premcheska+2 more
wiley +1 more source
Satralizumab Ameliorates Refractory Central Neuropathic Pain and Painful Tonic Spasms in Neuromyelitis Optica Spectrum Disorder: A Case Report. [PDF]
Matsuo J, Nakahara K, Hara Y, Ueda M.
europepmc +1 more source
The development of a nanobody for Nogo‐A, a potent neurite outgrowth inhibitor crucial in multiple sclerosis, is reported using a rational design approach. The nanobody targets the Nogo‐A ectodomain at the S1PR2 receptor‐binding region with submicromolar KD.
Vaidehi Roy Chowdhury+9 more
wiley +1 more source
A novel agent targeting APRIL: A new hope for elderly patients of IgA nephropathy. [PDF]
Liu X, Zuo L.
europepmc +1 more source
Objective A phase 2 trial tested different doses of the anti‐CD40 monoclonal antibody BI 655064 as an add‐on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo.
Martina Uzzo+5 more
wiley +1 more source
Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update. [PDF]
Tseriotis VS+10 more
europepmc +1 more source
Multiple Use of Regenerated Depth Filters in Antibody Purification Processes
ABSTRACT During the manufacturing of therapeutic antibodies, disposable depth filters are used after affinity chromatography to remove haze and process‐related impurities such as host cell proteins (HCP) and DNA known as critical quality attributes.
Bernhard Spensberger+5 more
wiley +1 more source
Research trends in anti-rabies virus monoclonal antibody: A bibliometric analysis. [PDF]
Liu C+7 more
europepmc +1 more source
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash+1 more
wiley +1 more source